These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 16549330)
1. What's new in pancreatic cancer treatment pipeline? Von Hoff DD Best Pract Res Clin Gastroenterol; 2006 Apr; 20(2):315-26. PubMed ID: 16549330 [TBL] [Abstract][Full Text] [Related]
2. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Burris H; Rocha-Lima C Oncologist; 2008 Mar; 13(3):289-98. PubMed ID: 18378539 [TBL] [Abstract][Full Text] [Related]
3. [Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs]. Wang ZY Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):641-5. PubMed ID: 20021856 [No Abstract] [Full Text] [Related]
4. Cancer drug trials show modest benefit: drugs target liver, gastric, head and neck cancers. Hampton T JAMA; 2007 Jul; 298(3):273-5. PubMed ID: 17635880 [No Abstract] [Full Text] [Related]
5. Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib. Wich C; Agaimy A; Strobel D; Wissniowski TT; Hartmann A; Ocker M World J Gastroenterol; 2010 Jul; 16(28):3592-6. PubMed ID: 20653070 [TBL] [Abstract][Full Text] [Related]
6. [New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents]. Yokoba M; Yanase N; Masuda N Gan To Kagaku Ryoho; 2005 Jun; 32(6):783-8. PubMed ID: 15984516 [TBL] [Abstract][Full Text] [Related]
7. Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells. Ricciardi S; Mey V; Nannizzi S; Pasqualetti G; Crea F; Del Tacca M; Danesi R Chemotherapy; 2010; 56(4):303-12. PubMed ID: 20714148 [TBL] [Abstract][Full Text] [Related]
8. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Petrelli A; Giordano S Curr Med Chem; 2008; 15(5):422-32. PubMed ID: 18288997 [TBL] [Abstract][Full Text] [Related]
9. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Siu LL; Awada A; Takimoto CH; Piccart M; Schwartz B; Giannaris T; Lathia C; Petrenciuc O; Moore MJ Clin Cancer Res; 2006 Jan; 12(1):144-51. PubMed ID: 16397036 [TBL] [Abstract][Full Text] [Related]
10. Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. Lee SJ; Lee J; Park SH; Park JO; Park YS; Kang WK; Lee J; Yim DS; Lim HY Invest New Drugs; 2012 Aug; 30(4):1540-7. PubMed ID: 21695438 [TBL] [Abstract][Full Text] [Related]
11. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. Ko AH; Youssoufian H; Gurtler J; Dicke K; Kayaleh O; Lenz HJ; Keaton M; Katz T; Ballal S; Rowinsky EK Invest New Drugs; 2012 Aug; 30(4):1597-606. PubMed ID: 21629990 [TBL] [Abstract][Full Text] [Related]
12. Targeted therapies in metastatic renal cancer in 2009. Bastien L; Culine S; Paule B; Ledbai S; Patard JJ; de la Taille A BJU Int; 2009 May; 103(10):1334-42. PubMed ID: 19338565 [TBL] [Abstract][Full Text] [Related]